- Prescribing Advice for GPs - https://www.prescriber.org.uk -

Drug Safety Update - June 2020

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for June 2020 (PDF).

This month readers are advised of revised measures to minimise risk of meningioma associated with the use of cyproterone acetate. It is now recommended that cyproterone is contraindicated in patients with previous or current meningioma (for all indications) and should only be considered for control of libido in severe hypersexuality or paraphilias in adult men when other interventions are inappropriate.

Readers are also reminded to be vigilant for signs and symptoms of bleeding when prescribing direct-acting oral anticoagulants (DOACs), especially in those patients with increased bleeding risks. There is an excellent summary of dose adjustments at differing levels of renal function for all four currently available agents. Readers are also advised of the available reversal agents.

The summary of letters to healthcare professionals includes details for drug trials of hydroxychloroquine and dexamethasone in the treatment or prevention of coronavirus (COVID-19), as well as several letters regarding product supply noting that Clenil®, Semglee® and Adoport® packaging or product may be in a different language or have a different appearance as imported stock is used to ease supply constraints.

Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.